Skip to content

Kymera Therapeutics KYMR Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$661.6M-21.8%
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
$53.17M+46.4%
Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Kymera Therapeutics (KYMR) reported comprehensive income (loss), net of tax, attributable to parent of -$75.23M in Q1 2026.
How has Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 17.3% year-over-year, from -$64.15M to -$75.23M.
What is the long-term trend for Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Kymera Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 32.2% compound annual growth rate (CAGR), from -$100.75M to -$308.07M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items like unrealized gains or losses on securities and foreign currency translation adjustments. It provides a more holistic view of the company's financial performance by capturing volatility that is excluded from traditional net income. Investors use this to evaluate the broader impact of market fluctuations and accounting adjustments on the company's total equity position.